We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi, Regeneron to Cut Cholesterol Drug Price in Exchange for Inclusion on Express Script Plan
Sanofi, Regeneron to Cut Cholesterol Drug Price in Exchange for Inclusion on Express Script Plan
In what Regeneron CEO Len Schleifer called a “paradigm-shifting agreement,” Sanofi and Regeneron sealed a deal with the pharmacy benefit manager Express Scripts cutting the price of their cholesterol drug Praulent (alirocumab) by up to $10,000 a year in exchange for easier access for Express Scripts patients.